Cymbalta

A will of iron

But is Cymbalta the best option?  Is there some reason to prefer it to its competitors?

Lilly expects to submit five drugs for US approval in 2013

Zyprexa's declining performance was partially offset by growth for other drugs, including depression treatment Cymbalta (duloxetine) and erectile dysfunction drug Cialis (tadalafil), meaning Lilly achieved flat total revenues of ... However, sales are

Lilly "plans to axe a third of US sales reps"

antidepressant Cymbalta (duloxetine) in the US later this year and osteoporosis treatment Evista (raloxifene) in 2014. ... Cymbalta and Evista have supported the business during the Zyprexa fall-off, but together brought in $6bn in sales last year –

New products help Lilly achieve flat Q4 sales

Former $5bn-a-year blockbuster Zyprexa (olanzapine) declined 49 per cent to $384m compared to the same period during 2011, with antidepressant Cymbalta (duloxetine) taking away some of the sting with ... The company is facing another major issue later

Lilly delivers upbeat earnings forecast for 2013

And further challenges are on the horizon as generic competition will emerge for big-selling antidepressant Cymbalta (duloxetine) later this year – placing another $5bn at risk of generic erosion – and $1bn ... Current products such as Alimta and

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]